Add BrightSurf on Google Email

Mass General Brigham


AI tool that estimates biological age from face photos could serve as prognostic biomarker for cancer

A new study suggests that an AI tool analyzing facial changes can serve as a prognostic biomarker for cancer prognosis. The researchers found that patients with higher biological aging rates had lower chances of survival, and the effect was strongest when photos were taken over longer intervals.

SourceMass General Brigham·JournalNature Communications·TypeComputational simulation/modeling·DateApr 28, 2026

New study finds blood test can predict Alzheimer’s disease progression years before symptoms or brain scan changes

Researchers found that a blood test for the biomarker pTau217 can predict the progression of Alzheimer's disease in cognitively healthy adults, detecting early signals years before symptoms appear. The study's findings may help push back the clock to enable simpler and earlier disease prediction.

SourceMass General Brigham·JournalNature Communications·TypeObservational study·DateApr 14, 2026

AI remains lacking in clinical reasoning abilities, according to study of 21 large language models

A study of 21 large language models found that they excel at accurate final diagnoses but falter at differential diagnoses, highlighting the need for human oversight in healthcare. The researchers developed a novel measure, PrIME-LLM, to evaluate AI's clinical competency across different stages of reasoning.

SourceMass General Brigham·JournalJAMA Network Open·TypeComputational simulation/modeling·DateApr 13, 2026

Research Spotlight: A new pulmonary embolism guideline, clinical advances and research updates, and a Mass General Brigham investigator’s insights

The new guidelines introduce five clinical categories to capture PE severity, emphasizing follow-up care and treatment considerations. Despite advances in diagnosis and treatment, PE remains a serious condition with substantial risk, highlighting the need for continued research and improvement.

SourceMass General Brigham·JournalJournal of the American College of Cardiology·DateApr 7, 2026

Targeted therapy improves long-term outcomes for patients with rare mutations driving lung cancer

A phase 1/2 clinical study found that pralsetinib improved durable responses with manageable safety profiles in patients with advanced or metastatic RET fusion-positive non-small cell lung cancer. The overall response rate was 78% and median duration of response was longer in patients with the CCDC6-RET fusion gene.

SourceMass General Brigham·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateApr 1, 2026

New genetic risk score better predicts diabetes, obesity and downstream complications

Researchers developed a comprehensive genetic risk calculator for metabolic disease by integrating genetic data from hundreds of thousands of people worldwide. The polygenic risk score outperformed existing disease-prediction models and predicted downstream morbidity and clinical interventions, particularly in non-European populations.

SourceMass General Brigham·JournalCell Metabolism·TypeRandomized controlled/clinical trial·DateMar 16, 2026

Romiplostim prevents serious side effect of chemotherapy in phase 3 trial

A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.

SourceMass General Brigham·JournalNew England Journal of Medicine·TypeExperimental study·DateMar 12, 2026

Trial finds vitamin D supplements don’t reduce covid severity but could reduce long COVID risk

A large randomized trial found that high-dose vitamin D3 did not reduce COVID-19 infection severity, but may impact long COVID outcomes. Researchers observed a promising signal that vitamin D supplementation could reduce long COVID symptoms, warranting further research in larger populations.

SourceMass General Brigham·JournalJournal of Nutrition·TypeRandomized controlled/clinical trial·DateMar 12, 2026

Research spotlight: Revolutionizing early detection of heterotopic ossification

A new study successfully detected heterotopic ossification (HO) weeks before current imaging techniques, enabling early intervention and potentially transforming HO prevention and treatment. The liquid biopsy method identified a unique gene signature associated with bone formation, achieving high accuracy in predicting at-risk patients.

SourceMass General Brigham·JournalNature Communications·TypeRandomized controlled/clinical trial·DateMar 3, 2026

Women’s risk of major cardiac events emerges at lower coronary plaque burden compared to men

Researchers analyzed data from nearly 4,300 stable outpatients with chest pain and found that women experienced similar rates of MACE as men despite having smaller plaque volumes. The study suggests incorporating sex into the interpretation of coronary plaque metrics may help advance tailored approaches to cardiac risk stratification.

SourceMass General Brigham·JournalCirculation·TypeObservational study·DateFeb 23, 2026

Targeted radiation therapy improves quality of life outcomes for patients with multiple brain metastases

A Phase 3 trial found stereotactic radiation targeting individual tumors improved symptom burden, cognitive outcomes, and daily function compared to whole brain radiation. Patients managed with stereotactic radiation also displayed better performance status and could remain more independent with everyday activities.

SourceMass General Brigham·JournalJAMA Oncology·TypeRandomized controlled/clinical trial·DateFeb 19, 2026

Study shows low-field MRI is feasible for breast screening

Researchers at Mass General Brigham have demonstrated the technical feasibility of using ultra-low field magnetic resonance imaging (MRI) for breast imaging, offering an alternative to existing methods and potentially reducing barriers to screening. Further study is needed to establish diagnostic performance and refine technology.

SourceMass General Brigham·JournalScientific Reports·TypeObservational study·DateFeb 19, 2026

Proton therapy leads to positive survival and quality of life outcomes for patients with lower grade glioma

A new study by Mass General Brigham highlights the efficacy of proton therapy in achieving excellent tumor control rates while minimizing side effects compared to traditional radiotherapy. Proton therapy limits radiation exposure to healthy tissue, potentially preserving cognition and hormone function.

SourceMass General Brigham·JournalNeuro-Oncology·TypeRandomized controlled/clinical trial·DateFeb 11, 2026

Personalized palliative care shows signs of improving quality of life for children with advanced cancer

A Mass General Brigham-led study found that integrating feedback and personalized palliative care can improve the quality of life for children with advanced cancer. The study showed significant improvements in symptoms and well-being for patients who received the intervention, highlighting the potential benefits of early palliative care.

SourceMass General Brigham·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateFeb 4, 2026

For people with traumatic brain injury and their caregivers, recovery of basic communication is an “acceptable” outcome

A study by Mass General Brigham found that individuals with traumatic brain injury and their caregivers consider recovery of basic communication an 'acceptable' outcome, challenging traditional assumptions about what constitutes a 'favorable' recovery. The study highlights the need for person-centered approaches to TBI outcome research.

SourceMass General Brigham·JournalCritical Care Medicine·TypeSurvey·DateFeb 3, 2026

Research spotlight: Discovering risk factors for long-term relapse in alcohol use disorder

Research identifies reduction in recovery focus as most prevalent and potent contributor to long-term relapse, emphasizing the importance of ongoing monitoring and proactive interventions. The study highlights the need for integrated biopsychosocial disease-management models to address complex relapse risk factors.

SourceMass General Brigham·JournalFrontiers in Public Health·TypeSystematic review·DateJan 29, 2026

Research Spotlight: a new “lab-on-a-disc” device paves the way for more automated liquid biopsies

Researchers developed an innovative centrifugal system called SpinEx that separates plasma, enriches EVs, and labels proteins in one device. The technology enables fast and automated EV isolation from small blood volumes, accurately distinguishing cancer from non-cancer samples and identifying specific tumor types.

SourceMass General Brigham·JournalNature Biomedical Engineering·DateJan 28, 2026

Parental firearm injury linked to increased mental health burden in children

A study published in the New England Journal of Medicine found that children whose parents were injured by firearms experience substantial mental health impacts, with a 42% increase in psychiatric diagnoses and 60% increase in mental health visits. Early, targeted interventions are needed to address this growing need.

SourceMass General Brigham·JournalNew England Journal of Medicine·TypeLiterature review·DateJan 28, 2026

Insights from brain’s waste-flushing system may improve diagnosis of idiopathic intracranial hypertension

Researchers used MRI analysis to measure glymphatic system activity, finding changes related to IIH stage and pressure levels. The findings suggest a noninvasive test could diagnose IIH more reliably, improving treatment options for patients with symptoms including headaches and vision loss.

SourceMass General Brigham·JournalJournal of Neuro-Ophthalmology·TypeExperimental study·DateJan 27, 2026

Patients struggle to measure blood pressure at home

A study found that one-third of patients in an at-home hypertension management program could not complete weekly readings, highlighting the need for more convenient and less burdensome monitoring tools. The researchers suggest innovative wearable devices that can passively collect blood pressure readings to reduce patient burden.

SourceMass General Brigham·JournalJAMA Cardiology·TypeObservational study·DateJan 21, 2026